Objective
Several among the most active anticancer drugs poison cellular DNA-topoisomerases (Topo) I and II. The mode of DNA binding is one of the most important but not the only factor in the formation of Topo-mediated ternary cleavable complexes. Therefore the molecular background of interactions within the supra-molecular complexes of enzymes, DNA and anti-tumour drugs should be investigated if the overall patterns of drug structure-activity relationships is to be clarified. The physical basis for cleavable complex formation by Topo-targeting drugs remains to be defined. This project is one of the first to study molecular interactions accompanying this effect, and to analyse the molecular basis of complex formation for the drugs purified with Topo I and II, with the DNA and within the ternary cleavable and reversed complexes by means of Raman, resonance Raman, and SERS techniques.
The main goal of the project is to elucidate the molecular interactions between drugs (specific Topo I, Topo II or dual Topo I and II inhibitors) and their targets, their selectivity for cancer cells and the mechanisms of drug sensitivity, resistance using the normal and drug-resistant cell lines. The microspectroscopic techniques available to the members of the consortium will make it possible to correlate structure-function relationships found in vitro with the intracellular interactions. Therefore it should be possible to design more selective Topo I and II inhibitors, and to shed light on the general mechanisms of action of Topo-targeting anti-tumour drugs.
The second goal of the project is devoted to the study of molecular background and structure-function relationships in the mechanism of interactions responsible for inhibition of human immunodeficiency virus (HIV) integrase by a variety of chemicals, including Topo inhibitors, antimalarial agents, and DNA binders. Each step of the HIV replication cycle represents a potential target for therapeutic intervention. The set-up of an in vitro retroviral DNA integration system using recombinant HIV integrase and oligonucleotides corresponding to the U5 end of HIV DNA will be used to identify several groups of drugs which are able to inhibit effectively HIV-1 integrase (e.g. caffeic acid phenethyl ester, flavon, chloroquine, and anthracyclines). The identified drugs will be studied by means of spectroscopic and microspectroscopic techniques within the scope of the project and their molecular interactions with the target will be analysed both in vitro and in living cells.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Data not available
Coordinator
51096 Reims
France
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.